title: Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.
abstract: Radiation therapy is the primary treatment in nasopharyngeal carcinoma (NPC), and the effect of radiation therapy is strongly related to the oxygen content of cancer cells. That means, it is imperative to balance the interactions between radiotherapy and anti-angiogenesis therapy when giving combination therapy to improve clinical outcomes. The complicated mechanisms between antiangiogenic agents and radiation involve many interactions between the cancer cells, vasculature, and cancer stroma. The proliferation and metastasis of cancer depends on angiogenesis, while rapid growth of cancers will cause hypoxia, which contributes to radioresistance. Antiangiogenic agents can modulate the cancer blood flow and oxygenation through target cancer vasculature, leading to increased radiosensitivity. This study discusses the mechanisms of the synergistic effect of the antiangiogenic therapy with radiation therapy in metastatic NPC, and reviews the data supporting this strategy as a promising treatment for metastatic NPC.
authors.affiliation: Department of Oncology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China. E-mail. 594286232@qq.com.
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Chen
authors.forename: Xin-Hua
authors.initials: XH
authors.lastname: Xu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002277:Carcinoma; D003131:Combined Modality Therapy; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism / Q000628:therapy*; D011836:Radiation Tolerance; D011878:Radiotherapy / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab